DexCom ( NASDAQ: DXCM ) has announced that people living with Type 1 diabetes in the Netherlands will be able to use a new tubeless Hybrid Closed Loop system the Omnipod 5 integrated with the Dexcom G6 Continuous Glucose Monitor, for an easier diabetes management experience. In the Netherlands, 0.1M people have type 1 diabetes, with an estimated 10,000 children affected, making it the most common autoimmune disease among children after asthma.
Dexcom G6 is available for reimbursement in the Netherlands via health insurers for children (18 and under), pregnant women (Type 1 and Type 2), women trying for pregnancy, and Type 1 hypo unaware users. "The rise of AID helps in that too. We can better monitor and adjust our treatment where necessary.
This makes it easier to manage diabetes." said Paediatrician Maartje Wijers-van Amelsfort M.D.
from the Slingeland hospital in Doetinchem. More on DexCom Dexcom: Positive Catalysts Ahead To Support Growth DexCom: Attractive Discount After Strong Earnings Results DexCom, Inc. (DXCM) Q1 2024 Earnings Call Transcript DexCom, Insulet, Tandem seen benefitting the most in diabetes survey - Wells Fargo Dexcom down 7% after hours despite quarterly beats, 2024 outlook updates.
